Brief
Sensydia raises $6 million to push catheter‑free cardiac device toward FDA review
The funding and a new CPT code move the device closer to reimbursable clinical use.
By Felo News Desk · Published
Sensydia announced a financing round of more than $6 million to advance its Cardiac Performance System (CPS), a catheter‑free heart‑assessment tool, toward FDA review and market launch.
CPS captures acoustic and electrical signals from the heart, uses artificial‑intelligence algorithms to translate them into pressure and function data, and is intended for clinicians treating heart‑failure and pulmonary‑hypertension patients in offices or clinics.
In July 2026, the Medicare‑approved Category III CPT code 1036T was introduced for non‑invasive hemodynamic exams that combine passive signal capture, algorithmic review and physician interpretation—the same workflow CPS employs. The new code and financing shift the device from a research prototype toward a billable office procedure.
Key facts
- Sensydia secured over $6 million in new financing for its Cardiac Performance System. (trendhunter.com)
- CPS provides pulmonary pressure readings without a catheter, using acoustic and electrical signals interpreted by AI. (trendhunter.com)
- Category III CPT code 1036T, introduced in July 2026, covers non‑invasive hemodynamic exams like CPS. (trendhunter.com)
- The funding aims to move CPS toward FDA authorization and reimbursable office use. (trendhunter.com)
Sources
- [1] trendhunter.com — originally reported as “Catheter-Free Cardiac Assessments”
